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Introduction
Multiple sclerosis (MS) is an inflammatory and neu-
rodegenerative demyelinating disease of the central 
nervous system (CNS) with onset usually in young 
adulthood; it is likely autoimmune in origin.1 
Prevalence and incidence rates vary with geography 
and ethnicity, with prevalence figures ranging from 2 
per 100,000 in Japan to greater than 100 per 100,000 
in Northern Europe and North America. Women are 
affected two to three times more frequently than men,2 
and there is evidence that this disparity is increasing 
in some, but not all, geographical areas.3 MS is usu-
ally diagnosed during the most active and productive 
period of life in the majority of individuals, with dis-
ability eventually developing in a sizeable proportion 
of patients. There is therefore a compelling need to 
understand whether modifiable factors may alter dis-
ease risk, as well as disease activity and progression.
The aetiology of MS is most certainly heterogeneous: 
multiple factors, both genetic and environmental, 
determine disease risk and these risk factors interact 
with one another in a complex manner.4 The strong-
est contributor to genetic susceptibility is the major 
histocompatibility complex (MHC). The HLA-
DRB1*1501-DRB5*0101 haplotype, in particular, 
shows a strong association with MS risk in 
Caucasians.5 Many other susceptibility gene variants 
have now been identified, although their effects are 
generally minor.6,7 The genetics of the HLA region, 
however, is complex with potential epistatic interac-
tions between DR haplotypes and heterogeneity 
depending on ethnicity.8 Notwithstanding this, for a 
substantial number of people who are genetically 
susceptible to MS, it does appear that non-genetic, 
potentially modifiable factors play a role in whether 
they develop the disease or not. In addition, some 
modifiable factors have been identified which are 
associated with disease activity and progression.9 
Together, this suggests that interventions could be 
developed to prevent some proportion of MS cases 
and/or alleviate the severity of the disease course.
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ECTRIMS held its fourth focused workshop on envi-
ronmental, modifiable risk factors for MS on 3–4 
March 2016 in Florence, Italy. The purpose of this 
report is to summarise the highlights from this meet-
ing and their implications for patient care and to iden-
tify avenues for future research that may generate 
more effective approaches to prevention and manage-
ment of MS.
Gene–environment interactions
More than 110 loci have been associated with MS 
onset in large, multicentre, genome-wide association 
studies, although the strongest association remains 
with the HLA-DRB1*1501-DRB5*0101 haplo-
type.6,7 Epidemiological studies have aimed to iden-
tify causal associations between gene–environment 
interactions or environment–environment interactions 
and MS risk.4
Among various research initiatives, the Swedish MS 
Registry has launched the development of the 
Epidemiology in Multiple Sclerosis (EIMS) and 
Genes and Environment in Multiple Sclerosis 
(GEMS) projects.10 Lifestyle questionnaires and 
extensive genotyping of subjects included in these 
cohort studies have enabled identification of environ-
mental and lifestyle MS risk factors and their possible 
interaction. The studies have shown interactions 
between MS HLA risk genes and smoking (both 
active and passive), Epstein–Barr virus (EBV) serol-
ogy, infectious mononucleosis (IM), adolescent obe-
sity and organic solvents. It is noteworthy that in the 
registry dataset 60% of all cases were associated with 
an interaction between EBV serology and HLA, with 
an additive effect.
In general, whether MS risk factors act in sequence and 
depend on each other or whether they act indepen-
dently and in an additive or multiplicative fashion is 
poorly understood. The fact that no factor has yet been 
shown to be present in all patients with MS, with the 
possible exception of the EBV in adult-onset MS, sug-
gests that causal pathways are likely to differ between 
individuals and would support an additive effect.11
Infections and vaccines
Research on infectious causes of MS is based on clini-
cal and pathological observations or experiments in 
animal models.12 Another approach involves the 
assessment of the extent to which an infectious agent 
could be implicated in the epidemiology of MS.13 In 
particular, the potential relationships between MS 
epidemiology and infections have been analysed in 
the context of the ‘hygiene’ and ‘old friends’ hypoth-
eses (see below). A common aspect to both is that a 
widespread microbe, rather than a rare pathogen, may 
be involved in MS. Overall, epidemiological data pro-
vide some support to the ‘hygiene’ hypothesis, but 
with the additional proviso for a key role of EBV in 
determining MS risk.
A correlation between ‘hygiene’, as defined by 
reduced early life exposure to infectious agents, and 
MS risk has long been noted. It has been suggested 
that better hygiene or lower exposure to infectious 
agents in childhood can favour the development of a 
Th1 pro-inflammatory cellular immune response, 
whereas exposure to multiple infections in childhood 
could deviate the immune response towards a regula-
tory T-cell phenotype.14
The ‘hygiene hypothesis’ may explain some epide-
miological findings, including a lower incidence of 
MS in developing countries (with poorer hygiene) as 
compared to countries with higher socioeconomic 
standards, and an increased MS prevalence associated 
with improving education and socioeconomic status 
(SES) in some early investigations,14 although more 
recently the inconsistency of data surrounding SES 
and MS risk has been recognized.15 This hypothesis is 
also corroborated by the observation of an increased 
risk of MS with a late age at infection with EBV and 
manifestation as IM.16 However, the hypothesis does 
not completely fit with epidemiological MS data, 
since those subjects who are seronegative for EBV 
infection have a very low MS risk status. This repre-
sents a ‘paradox’: if the hygiene hypothesis was valid 
for MS, these individuals would be expected to be at 
high MS risk because the lack of infection from EBV 
(an almost ubiquitous pathogen) is a marker of a 
highly hygienic environmental status.14 This paradox 
could be solved if EBV itself is a contributory cause 
of MS – that is, the adverse effect of good hygiene on 
MS risk becomes manifest only after EBV infection.
EBV
The identification of the paradox described above, 
and the demonstration that EBV-seronegative indi-
viduals are virtually immune to MS until the time they 
are infected with EBV but are at high MS risk after 
EBV infection,17 provides convincing evidence that 
EBV stands out as the most important infectious agent 
that may explain many of the key features of MS 
epidemiology.
Furthermore, EBV and IM (which is usually caused 
by primary EBV infection during adolescence) have 
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been linked to MS onset in several epidemiological 
studies, both retrospective and prospective in design, 
and in meta-analyses and basic research. A number of 
EBV-associated autoimmune disorders and malignan-
cies may develop after an extended period of latency 
following primary infection. In particular, a history of 
IM is associated with a two- to threefold increased 
risk of developing MS. Moreover, an immune 
response to the CD4+ T-cell antigen EBNA1 is promi-
nently elevated in MS subjects, and titres of anti-
EBNA1 antibodies appear to increase the risk of the 
disease in a dose-dependent manner.14
However, the link between EBV and MS by itself 
cannot explain the decline in risk among migrants 
from high to low MS prevalence areas.13,18 This 
decline may suggest that either EBV strains in low-
risk areas have less propensity to cause MS or that 
other infectious or non-infectious factors modify 
the host response to EBV or contribute to determine 
MS risk.14
Proposed mechanisms of action for the association of 
EBV with MS include molecular mimicry, bystander 
damage to the CNS by EBV-specific T cells, induc-
tion of an immune response to EBNA1 antigen, 
chronic infection of B cells and an indirect mecha-
nism due to reactivation of human endogenous retro-
viruses (HERV), such as HERV-W.14
In conclusion, while overall evidence strongly sup-
ports a role for EBV in MS aetiology, the exact mech-
anism by which EBV infection can predispose to MS 
remains elusive. Further studies are strongly advo-
cated to elucidate the nature of this association. In 
addition, further work should investigate whether 
EBV infection can also drive subsequent disease 
activity or progression in those with established MS.9
Implications for prevention and patient care
Based on the above evidence on the role of EBV in 
MS, there could be relevant implications for thera-
peutic/preventive strategies. Antiviral therapy, based 
on nucleoside analogues, has been studied princi-
pally in EBV-related lymphoproliferative disorders, 
but it is generally ineffective, probably because the 
virus is in a latent phase of its cycle. Research into 
the development of prophylactic and therapeutic 
EBV vaccines has started. EBV vaccination, initially 
targeting IM, is under investigation, whereas induc-
tion of a viral neutralisation antibody response pre-
venting primary infection may be appropriate for the 
prevention of primary EBV infection in the general 
population. An alternative strategy to induce a 
cell-mediated immunity to control latent-infected 
cells in persistently infected individuals may have a 
role in the prevention of EBV-related malignancies 
and autoimmune disorders.19
Due to the capability of the virus to establish latent 
infection in B cells,14 in those who already have MS, 
potential therapeutic strategies include B-cell-
depleting therapies and anti-retroviral drugs. 
Rituximab, ocrelizumab and ofatumumab are mono-
clonal antibodies targeting CD20+ B cells which have 
shown disease-ameliorating effects in clinical trials.20 
The role of HERVs in MS pathogenesis is under 
investigation, and agents such as raltegravir, a retrovi-
ral integrase inhibitor, have been tested in clinical tri-
als for the treatment of MS.21,22
The Bacillus Calmette–Guérin (BCG) vaccine is 
under study as a possible option for an ‘intermedi-
ate’ preventive strategy, based on vaccination of 
those who are at high risk of developing MS. In a 
randomised double-blind trial on subjects with clini-
cally isolated syndrome (CIS), BCG vaccine, as 
compared to placebo, was associated with signifi-
cantly reduced development of gadolinium-enhanc-
ing lesions at magnetic resonance imaging (MRI) for 
a 6-month period before starting immunomodulating 
therapy.23 BCG vaccine may act as a tumour necrosis 
factor (TNF)-inducer, and preclinical studies have 
shown that it may have a neuroprotective effect.23 A 
study with BCG vaccine in subjects with radiologi-
cally isolated syndromes (RIS) is in preparation 
(Marco Salvetti, MD, University of Rome, personal 
communication).
Parasites
The ‘old friend’ hypothesis suggests that early expo-
sure to large numbers of parasites could protect 
against development of MS in later life.24 Indeed, the 
risk of MS shows an inverse correlation with helminth 
infections, and it is possible that helminths – which 
have been parasitic throughout human evolution – act 
as immune regulators in people naturally infected 
with them. Helminths can establish a life-long equi-
librium with the host, favouring the release of anti-
inflammatory cytokines and expansion of regulatory 
T and B cells. There are some positive results with the 
use of helminths as a potential treatment in animal 
models of MS. A few preliminary clinical studies with 
helminth therapy have been conducted in MS 
patients.24 A small controlled trial of Trichuris suis 
ova failed to show any benefit.25 Future research 
should focus on the host–parasite interactions result-
ing from specific molecules isolated from parasites, 
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perhaps providing a more targeted approach and min-
imising adverse effects related to helminth therapy.
Vitamin D deficiency
Vitamin D and MS risk
A substantial evidence base now exists to support an 
association between vitamin D deficiency and low 
levels of its metabolite 25-hydroxyvitamin D3 
(25(OH)D) in the onset and development of MS.26 
Experimental studies have shown that vitamin D has 
potent immunomodulatory activity.26 It may have an 
anti-inflammatory role in the secondary lymphoid 
organs and the CNS, and it may also have neuro- and 
myelin-protective and/or myelin-regenerative effects 
in the CNS.27 Genetic effects may also contribute 
to MS risk as genes associated with vitamin D 
metabolism have been identified in an MS genome 
association study. In addition, transcription of the 
HLA-DRB1*1501 locus is regulated by vitamin D.28
The bulk of evidence for this association is derived 
from extensive epidemiological research based on 
different study designs. Collectively, the results sup-
port the importance of vitamin D sufficiency in ado-
lescence and adulthood, up to the time of MS onset. 
Furthermore, they also suggest the importance of 
vitamin D in childhood or even in utero.14 Recently, 
the role of maternal vitamin D deficiency during 
pregnancy has been documented in a nested case–
control study by the Finnish Maternity Cohort,29 
where insufficient maternal vitamin D levels during 
pregnancy were associated with an almost twofold 
increased risk of MS in the offspring.
The causality of the relationship between vitamin D 
and MS risk is further supported by the results of 
Mendelian randomisation studies. These results pro-
vide compelling evidence that vitamin D deficiency is 
an independent risk factor for MS, although they do 
not exclude a contribution of other factors. Some 
uncertainty remains about whether there is a critical 
timing of exposure to low 25(OH)D levels and what 
absolute level of 25(OH)D is associated with increased 
MS risk.30,31
Vitamin D and MS disease activity or progression
Vitamin D deficiency has also been associated with 
increased disease activity or progression in subjects 
with already established disease. The findings of a 
few small therapeutic trials using vitamin D in MS 
patients have been inconsistent,32–37 and none of these 
studies was powered sufficiently to observe a 
treatment effect. Large randomised interventional 
clinical trials in the United States, Europe and 
Australasia are currently evaluating vitamin D sup-
plementation to decrease the risk of relapses (Table 
1). These studies should also help to define appropri-
ate methods of dosing to obtain optimal serum vita-
min D levels that may reduce clinical MS activity.
Finally, observational studies based on the datasets 
from Phase III trials of interferon beta-1b support an 
influence of vitamin D on the disease course. In the 
betaferon/betaseron in newly emerging MS for initial 
treatment (BENEFIT) trial, 25(OH)D levels in the 
first year of the study were studied in association with 
clinical and MRI outcomes after 5 years, which helped 
minimise the possibility of reverse causation.42 The 
study results showed that higher serum 25(OH)D lev-
els early in the course of MS robustly predicted a 
lower degree of clinical and MS activity, MRI lesion 
load, brain atrophy and clinical progression over the 
5 years of follow-up. In the large cohort from the 
betaferon/betaseron efficacy yielding outcomes of a 
new dose in MS patients (BEYOND) trial in relaps-
ing-remitting multiple sclerosis (RRMS), sub-group 
analyses based on the patient vitamin D status were 
possible.43 There were profound geographical differ-
ences in patient vitamin D status; the analyses showed 
a decreased risk of accumulating new active lesions at 
MRI in subjects with higher levels of 25(OH)D and 
suggested as ‘best guess’ an optimal level of 25(OH)
D corresponding to 100 nmol/L. In this regard, further 
investigations are needed to identify definitively opti-
mal levels of vitamin D and to determine whether 
these results apply to different races or ethnicities, to 
patients with the secondary or primary progressive 
course of MS and to patients receiving drugs other 
than interferon beta-1b.
Implications for prevention and patient care
Questions remain as to whether the MS incidence or 
ongoing disease activity and progression can be 
reduced by vitamin D supplementation. Available 
data suggest that MS risk is reduced at an average 
serum 25(OH)D level above 100 nmol/L, currently 
achieved by only one-fifth of the at-risk population in 
the United States, and in a smaller proportion in most 
at-risk European populations.14 This level of vitamin 
D could be reached by taking 2000–4000 IU/day of 
vitamin – a dose that is well above current recommen-
dations, but has not been associated with major 
adverse outcomes to date.14
Due to the above uncertainties, many experts believe 
that more conclusive experimental evidence should 
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be awaited before implementing nationwide univer-
sal vitamin D supplementation programmes aimed at 
reducing the risk of new cases of MS. However, for 
many individuals, including those living in areas 
where vitamin D deficiency is highly prevalent and 
those at high MS risk due to their family history, in 
addition to CIS and MS patients, the use of vitamin 
D supplements may represent a reasonable choice, 
considering, on the one hand, the strength and qual-
ity of evidence available and, on the other hand, the 
low risk of adverse events using the vitamin D dose 
suggested above.
Lifestyle risk factors
Cigarette smoking
Cigarette smoking and MS risk. There is extensive 
and robust evidence that cigarette smoking, both active 
and passive, is a risk factor for MS onset. Smoking 
increases the risk of MS by approximately 50% in a 
number of epidemiological studies,44 and there appears 
to be a consistent dose–response relationship with 
cumulative smoking dose.45,46 Elevated levels of coti-
nine (a surrogate marker for nicotine) were detected in 
blood samples taken before the development of MS, 
supporting epidemiological evidence for the increased 
risk of MS in individuals who smoke.46 Differential 
changes over time in smoking behaviour between men 
(with decreasing numbers of smokers) and women 
(with a relatively constant number of smokers) over 
the past several decades could, in part, explain the 
increase in the female:male ratio in MS incidence 
noted in a few regions.14,47 The critical period for 
exposure to cigarette smoke is unclear, with some 
studies detecting no effect of age,45 and others 
observing increased susceptibility to MS with expo-
sure during adolescence or young adulthood.46
Cigarette smoking and MS disease activity or pro-
gression. There is also some evidence of negative 
effects of smoking on disease course and progres-
sion. Smoking has been associated with a faster tran-
sition from onset of symptoms to a definitive MS 
diagnosis,48 a more rapid shift to the secondary pro-
gressive phase of the disease, and progression in 
disability.49,50
Numerous mechanisms have been proposed to explain 
the adverse effects of smoking on MS risk, including 
effects on demyelination, disruption of the blood–
brain barrier, immunological effects and increased 
nitric oxide and nitric oxide metabolites, but all 
remain speculative. The observation that tobacco 
Table 1. Ongoing randomised clinical trials of vitamin D in MS patients.
Trial name SOLAR38 VIDAMS39 VITADEM EVIDIMS40 PrevANZ41 D-Lay-MS
Location Europe USA Spain Germany Australasia France
Participants 230 RRMS 172 RRMS 100 RRMS 80 RRMS or CIS 240 CIS 316 CIS
Vitamin D3 
intervention
7000 IU/day 
4 weeks up to 
14,000 IU/day 
92 weeks vs 
placebo (add on to 
IFNB-1a)
5000 vs 600 IU/
day (add on to 
galtiramer acetate)
4000 IU/day vs 
placebo
20,400 IU/every other 
day vs 400 IU/every 
other day (add on to 
IFNB-1b)
1000 vs 5000 
vs 10,000 IU/
day vs placebo
100,000 IU/
every 14 days vs 
placebo
Duration 96 weeks 96 weeks Not known 18 months 48 weeks 2 years
Primary 
outcomes
Mean number 
CUA lesions 
at week 48; 
proportion relapse 
free at the end of 
study
Percentage of 
participants having 
relapse by EOS
Percentage of 
participants 
having relapse 
by EOS
Number of new T2 
lesions
Conversion to 
CDMS/MDMS
Conversion to 
CDMS/MDMS
Secondary 
outcomes
Annualised relapse 
rate, EDSS change 
at predefined time 
points
Annualised 
relapse rate, EDSS 
change, number of 
new active lesions, 
lesion volume
EDSS change, 
number of new 
active lesions, 
number of new 
T2 hyperintense 
lesions
Annualised relapse 
rate, percentage of 
relapse free at EOS, 
EDSS and MSFC, 
change at predefined 
time points
Number of 
relapses, number 
of new lesions, 
new active 
lesions, EDSS 
change, EQ5D
End of study 2015 2016 Not known 2016 Not known 2017
MS: multiple sclerosis; RRMS: relapsing remitting multiple sclerosis; CIS: clinically isolated syndrome; IFNB: interferon beta; CUA: combined unique activity; 
EOS: end of study; CDMS: clinically definite multiple sclerosis; MDMS: McDonald multiple sclerosis; EDSS: expanded disability status scale; MSFC: multiple 
sclerosis functional composite; EQ5D: European quality of life 5 dimensions.
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smoking, but not Swedish tobacco snuff, was associ-
ated with an increased MS risk suggests that combus-
tion and/or inhalation are required to increase the risk 
of MS. Moreover, the increased risk of MS associated 
with organic solvents51 was found to be higher in 
never smokers, suggesting lung irritation may play a 
crucial role,52 which is also supported by studies in 
animal models.53
Implications for prevention and patient care. Based 
on the above data, from a public health perspective, 
the impact of smoking and passive smoking on both 
MS onset and subsequent progression appears consid-
erable. Promoting smoking cessation may be one of 
the most straightforward interventions available to 
reduce the incidence of MS.
Individuals with a history of MS in the family should 
be informed regarding the impact of smoking on the 
risk of developing MS, and the importance of pre-
venting their children from being exposed to passive 
smoke.
Given the potential prognostic implications, patients 
with MS should be advised to stop smoking, to lessen 
risks for comorbidities and to avoid possible aggra-
vating MS-related disability.
Body mass index
Body mass index and MS risk. In epidemiological 
studies, overweight/obesity is associated with a 
two- to threefold increased risk of MS.54–59 An inter-
action with other risk factors, including vitamin D 
status and genetic predisposition, has also been doc-
umented. Data from the Swedish EIMS study have 
shown that individuals whose body mass index 
(BMI) exceeded 27 kg/m2 at age 20 had a twofold 
increased risk of developing MS in comparison with 
subjects with normal body weight.57 In a further 
Swedish study using EIMS and GEMS data, strik-
ing associations were observed between BMI status 
and HLA genotype with regard to MS risk. Obese 
individuals with the MS-associated HLA genotype 
(presence of the HLA-DRB1*1501 allele and 
absence of the HLA-A*02 allele) had a 16-fold 
greater probability of developing MS compared to 
non-obese individuals without this genetic risk fac-
tor.58 Other population-based studies have shown 
that the risk of MS is increased in obese children 
(aged 7–13 years)60 and adolescents (aged 12–
18 years),61 with the effects being most pronounced 
in girls. As for the possible mechanism of action, it 
is speculated that a chronic, low-grade inflamma-
tory state can develop as a result of the part played 
by adipocytes in several metabolic pathways. High 
levels of leptin, an adipokine secreted by adipose 
tissue, have been associated with reduced regula-
tory T-cell activity and increased disease severity in 
animal models.62,63
BMI and MS disease activity or progression. There 
is also some evidence of a negative impact of obe-
sity on disease-related outcomes in those with MS. 
A higher BMI has been associated with a poorer 
response to interferon beta-1b in MS patients.64 
Moreover, obesity has been associated with 
increased T1 lesion volume at MRI,65 higher dis-
ability levels in a cohort of MS subjects who were 
obese compared with those of normal weight66 and 
in patients at MS diagnosis.67
Implications for prevention and patient care. Clearly, 
educational interventions should not take BMI as the 
only indicator of health status and should focus more 
broadly on lifestyle. Adolescents and young adults at 
high risk of developing MS should be counselled on 
the need to modify their lifestyle to mitigate their risk. 
Patients with MS should be encouraged to modify 
their lifestyle in order to reduce the negative impact of 
obesity on disease-related outcomes and the risk of 
associated comorbidities.
Other risk factors
Salt
There is some experimental information on the 
implications of dietary salt on the pathogenesis of 
CNS autoimmunity. Studies using animal models of 
MS have shown that high salt diet promotes patho-
genic T-cell responses and aggravates autoimmun-
ity, suggesting that high dietary salt intake may 
promote CNS autoimmunity and increase the risk of 
MS.68 These findings have not as yet been demon-
strated in clinical studies, but it would seem prudent 
for those at high risk of developing MS, and perhaps 
those already with MS, to moderate salt intake as a 
lifestyle choice.
Alcohol and caffeine
The Swedish EIMS and GEMS studies have assessed 
the possible association between alcohol and caffeine 
consumption and the risk of developing MS. A dose-
dependent inverse association between alcohol con-
sumption and MS risk was statistically significant in 
both men and women. In addition, the detrimental 
effects of smoking were more pronounced among 
non-drinkers.69
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Studies in animal models of MS have shown that caf-
feine may decrease the risk of developing the disease, 
possibly because of its neuroprotective properties and 
its role in the suppression of the production of proin-
flammatory cytokines.70 Data from population-based 
studies showed that the risk of MS was substantially 
reduced in individuals reporting a high coffee con-
sumption.71 However, in two large cohorts of women 
participating in the Nurse Health Study, the associa-
tion between MS risk and alcohol or caffeine intake 
was not confirmed.72 Therefore, due to limited 
research and inconsistent findings, caution is needed 
in interpreting these results and their significance 
warrants further investigation.
Stress
It has been suggested that psychological stress may 
play a role in the risk of MS, but the evidence in the 
field is limited and interpretation is difficult due to 
methodological issues and complexities in the defini-
tion and quantification of stress. A number of nation-
wide studies have been performed in Denmark. In the 
first study, parents exposed to the loss of a child had 
an increased risk of MS which was significant only 
when follow-up was at least 8 years.73 In the second 
study, there was little evidence for a causal associa-
tion between major stressful life events, such as 
divorce or the loss of a child or a spouse, and subse-
quent MS risk.74 A third study focused on the associa-
tions between stressful life events occurring in 
childhood (parental divorce, parental death, death of a 
sibling) and subsequent risk of MS reported only 
weak or modest associations.75
As for the potential impact of stress on disease activity, 
severe stress associated with war increased the fre-
quency of MS relapses.76 A meta-analysis of 14 studies 
showed that non-traumatic stressful life events were 
associated with an increased risk of disease exacerba-
tion. However, the association between the stressors 
and MS exacerbation is complex and no firm conclu-
sions can be drawn because measurement of effects was 
heterogeneous between studies.77 It has been postulated 
that the control of immune function by the major stress 
systems is impaired in MS and the endogenous inhibit-
ing systems may become inefficient against inflamma-
tion. This hypothesis should be tested in prospective 
epidemiological studies that employ endocrine, immu-
nological and MRI activity markers.78
Comorbidities
Interest in MS-related comorbidities is increasing. 
Most studies have focused on the presence or impact 
of comorbidities in patients with MS. Comorbidities 
have been associated with delays in diagnosis and 
disability progression.67 Modifiable comorbidities 
arise directly or indirectly from the primary disease 
(e.g. osteoporosis due to reduced mobility) and their 
management impacts overall patient outcomes. The 
interaction between MS and comorbidities is com-
plex. For example, comorbidities may affect deci-
sions on initiation of disease-modifying drugs 
(DMDs)79 and DMDs may increase the risk of cer-
tain comorbidities or they may be contraindicated if 
these comorbidities are already present.80 Moreover, 
common cancers may be diagnosed less frequently 
in MS patients because of MS-related immunologi-
cal changes, the adoption of a healthier lifestyle fol-
lowing an MS diagnosis or a delay in cancer 
detection.67
Gaining a better understanding of MS comorbidities 
may provide insight into the underlying disease pro-
cesses and promote the health and wellbeing of MS 
patients.
Implications for patient care
Comorbidities in MS are finally being given the pro-
file and importance their potential impact warrants. 
MS neurologists are advised to help prevent comor-
bidities and to systematically pursue early diagnosis 
and optimal treatment of modifiable comorbidities, 
which may produce substantial improvements in 
patient quality of life.80
The gut microbiota–brain axis
There is growing evidence implicating gut micro-
biota in the starting phase of several autoimmune 
diseases. As for MS, the stimuli triggering the auto-
immune response have been commonly attributed 
to environmental factors, in particular microbial 
infections. However, using the relapsing-remitting 
mouse model of spontaneously developing experi-
mental autoimmune encephalomyelitis, it has been 
shown that the commensal gut flora – in the absence 
of pathogenic agents – is essential in triggering 
immune processes, leading to a relapsing-remitting 
autoimmune disease driven by myelin-specific 
CD4+ T cells.81,82
Further research is now ongoing to determine the 
composition of the intestinal microbiota associated 
with an increased susceptibility to MS,83,84 in addition 
to disease outcomes in those already with MS,85 and 
this research may provide a conceptual basis for 
exploring new, less invasive treatment strategies.
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Achievements, gaps in knowledge and future 
perspectives
Achievements
Over the past decades much progress has been made 
in the identification of genetic and environmental, 
modifiable risk factors for the onset of MS, including 
the role of EBV, vitamin D levels, tobacco smoking 
and BMI (Table 2). These successes have resulted in 
neurologists being able to provide some guidance on 
ways to reduce risk in patients’ relatives, CIS and RIS 
subjects and to MS patients regarding lifestyle modi-
fication to potentially alter their clinical course.
The literature provides estimates that assist in deter-
mining the specific proportion of cases of MS that 
could be prevented through prevention of the above 
four major environmental risk factors.86 In particular, 
considering preventive interventions to occur sequen-
tially, and under specific assumptions related to the 
increased risk associated with each risk factor and the 
prevalence of exposure in the population, it has been 
calculated that smoking avoidance would produce 8%, 
vitamin D supplementation 44%, obesity prevention 
15% and IM prevention 12% reduction. Together, cur-
tailing these risk factors may prevent over 60% of MS 
cases. An EBV vaccine or other intervention that mod-
ulates EBV infection or the immune response to EBV 
could potentially prevent around 90% of MS cases.
Gaps in knowledge and future perspective
Most of the existing data concerning established 
risk factors for MS are derived from RRMS and are 
naturally dominated by women, so future investiga-
tions are warranted in the primary and secondary pro-
gressive forms of MS, and in men, that look for 
modifiable factors to decrease disease risk and possi-
bly ameliorate the subsequent disease course.
Moreover, our understanding of the pathogenic mech-
anisms underlying the identified risk factors is limited 
or mainly speculative. An in-depth elucidation of how 
these factors interfere with the development of MS, or 
with disease outcomes in those with MS, could lead to 
new approaches to prevention and treatment.
Future research should also focus on novel, emerging 
risk factors for which evidence is limited or conflict-
ing to date. To achieve these goals, further efforts 
should necessarily reinforce the multidisciplinary 
approach, combining basic and epidemiological 
research. In this context, there may be an increasing 
role for ‘omic technologies’ in elucidating pathogenic 
mechanisms due to their abilities to give a snapshot of 
the activity of cells, tissue and organisms at individual 
points in time.14 Future genetic studies may reveal 
mechanisms that can be modulated by developing 
novel therapeutic strategies. Epidemiological stud-
ies of gene–environment interactions can confirm 
causal associations, and epidemiological methodol-
ogy can provide additional evidence of associations 
suggested by genetic studies. Meta-analyses are 
powerful ways of combining data and highlighting 
consistent patterns among studies. It is possible that 
traditional epidemiological methods may soon 
become more efficient by the use of social media 
and mobile technologies in tracking individuals 
included in epidemiological surveys.87
Table 2. Achievements and challenges: key points.
The aetiology of MS is multifactorial with both genetic and non-genetic determinants contributing to the risk of the 
disease
Four environmental factors – EBV infection, low levels of vitamin D, cigarette smoking and increased BMI – are 
notable for robust evidence supporting their association with the disease
Primary infection with EBV and a history of IM double an individual’s risk of MS, with elevated antibody titres to 
EBV nuclear antigen being observed before the disease onset
Longitudinal studies of vitamin D supplementation and pre-onset serum levels of 25(OH)D support a protective role 
of vitamin D on MS risk
Cigarette smoking (both active and passive) increases the risk of MS by two to three times
Increased BMI is associated with two- to threefold increased risk of MS and female adolescents are at higher risk
Each of the above factors may interact in a complex manner with other genetic and non-genetic determinants
Our understanding of the mechanisms by which EBV infection, vitamin D, cigarette smoking and increased BMI 
influence the risk of MS are limited or mainly speculative and further research is required
There is some – albeit not definitive – evidence that vitamin D and cigarette smoking may also influence the 
subsequent MS disease course (relapses and/or progression)
MS: multiple sclerosis; EBV: Epstein–Barr virus; BMI: body mass index; IM: infectious mononucleosis; 25(OH)D: 25-hydroxyvita-
min D3.
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Furthermore, a major gap in knowledge is under-
standing interactions between different genetic and 
environmental risk factors. Clarifying these interac-
tions and modelling all known risk factors could ena-
ble robust ‘risk stratification’ and, possibly, the 
evaluation of an ‘individualised’ risk estimate, in 
order to identify those individuals who may benefit 
most from preventive strategies.
Some preliminary attempts at combining risk factors 
have been undertaken.11 The most comprehensive 
study to date involved the combination of 16 genetic 
risk loci, sex, and EBV titres into a prediction model.88 
However, the model fell short of being clinically use-
ful, and more detailed studies of these and additional 
risk factors in large cohorts are needed to better 
understand their predictive power in combination.
Finally, there is preliminary work on environmental 
factors, vitamin D, smoking and obesity in particular, 
as potential modifiers of the disease course and 
response to DMDs,89 a field that warrants further 
research.
Overall, although changes in environmental and 
nutritional factors would surely not eradicate MS 
completely, they may account for a large number of 
cases and further progress in this field could have a 
dramatic impact on the occurrence of the disease. 
Some of these factors may also impact the subsequent 
disease course in those who develop MS and hence 
inform the management of the disease.
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